Table 1.

Demographic and clinical information.

	FM-only with complete silencing		FM-only with incomplete silencing		PM/FM mosaic		p1	p2	p3	p4
	n	M ± SD	n	M ± SD	n	M ± SD
Age	19	14.6 ± 9.48	29	13.3 ± 7.29	14	16.8 ± 14.8	0.562	0.679	0.519	0.285
FSIQ	9	48.6 ± 13.4	18	43.9 ± 5.74	9	52.6 ± 9.06	0.067	0.211	0.351	0.024
ADOS CSS	17	6.06 ± 2.38	26	7.50 ± 1.45	12	6.67 ± 1.83	0.050	0.016*	0.390	0.205
Seizures (% lifetime presence)	19	10.5%	29	17.2%	12	0.0%	0.383	0.687	0.510	0.298
Country (% Australian)	19	15.8%	29	37.9%	14	42.9%	0.178	0.119	0.122	0.999
Medicated (% ≥ 1 medication)	19	52.6%	29	58.6%	14	28.6%	0.190	0.770	0.286	0.104
Stimulant	19	31.6%	29	27.6%	14	14.3%	0.566	0.999	0.416	0.456
SSRI	19	21.1%	29	27.6%	14	7.1%	0.318	0.739	0.366	0.231
Antipsychotic	19	5.3%	29	17.2%	14	7.1%	0.512	0.381	0.999	0.645
AAA	19	5.3%	29	0.0%	14	7.1%	0.279	0.396	0.999	0.326
SNRI	19	0.0%	29	0.0%	14	7.1%	0.226	NA	0.424	0.326
Benzodiazepine	19	0.0%	29	0.0%	14	7.1%	0.226	NA	0.424	0.326

P-values highlighted in bold were significant prior to adjustment for multiple comparisons.

FM full mutation, PM premutation, M mean, SD standard deviation, NA not applicable, FSIQ full scale IQ, ADOS CSS autism diagnostic observation schedule calibrated severity score, SSRI selective serotonin reuptake inhibitor, AAA alpha adrenergic agonist, SNRI selective norepinephrine reuptake inhibitor.

p-value (p) for comparing the means between ¹three groups; ²FM-only with complete silencing and FM-only with incomplete silencing; ³FM-only with compete silencing and PM/FM Mosaic; ⁴FM-only with incomplete silencing and PM/FM mosaic.

*P-value remained < 0.05 after adjusting for multiple comparison using Bonferroni correction method.